USPTO serial 79407821
TRANSFUSIUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 26, 2025
- Examiner
- CORWIN, KEVIN SCOTT
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TRANSFUSIUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Deborah L. Shapiro
Deborah L. Shapiro Moses & Singer LLP405 Lexington AvenueThe Chrysler BuildingNew York, NY 10174Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drugs, in particular medicines made from blood components, fractions and preparations, with said medicines being for the treatment of diseases and disorders of the blood; Living cells and cell fragments for medical purposes, namely, red blood cell concentrates; Living cells and cell fragments for medical purposes, namely, platelet concentrates; Living cells for medical purposes, namely, leukocyte preparations of white bloods cells for medical purposes; blood plasma, blood for medical and medical diagnostic purposes; blood cells for medical purposes; Blood components, fractions and preparations, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for injection, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for automatic transplantation, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components, fractions and preparations for autologous transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood, blood fractions and blood components for medical, therapeutic, and prophylactic purposes, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Blood components for medical use, namely, blood plasma, blood substitutes for human use; Blood plasma; Cells for medical use, namely, blood cell preparations; Sanitary preparations for medical purposes; Finished medical products, namely, human blood for medical purposes and blood plasma; Pharmaceutical preparations for the treatment of bleeding disorders, heart disease, cancer; Immunotherapeutic and immunoprophylactic preparations in the nature of blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; Living cells for medical purposes, namely, leukocyte preparations; Living cells and cell fragments for medical purposes, namely, platelet and red blood cell concentrates, quarantine plasma, fractionated plasma; clinical medical reagents for processing human blood and blood components for use in blood transfusions and for extracorporeal blood processing stored in bags, bottles, syringes and similar containers for storing substances such as these for medical purposes; Pharmaceutical products and preparations, in particular infusion and transfusion solutions in the nature of blood, blood plasma, and bloods substitutes for human use and pharmaceutical preparations for the treatment of blood diseases and disorders; Pharmaceutical blood plasma preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood preparations for the treatment of blood diseases, blood disorders; Pharmaceutical blood products, namely, pharmaceuticals for the treatment of blood diseases, blood disorders; Cell material for autotransplantation and autotransfusion, cells for medical use; Cell material for transplantation and transfusion, namely, cells for medical use; Cell material for medical, therapeutic and prophylactic purposes, namely, cells for medical purposes | ACTIVE | — |
| 035 | Advertising services; Arranging advertising events, namely, organizing events for advertising purposes; Advertising services for others, namely, developing advertising campaigns for others for attracting donors of blood and blood components; Advertising services to create brand identity for others in all media, including radio, television, cinema, print, videotext, on-line and via teletext advertising; Promoting the goods and services of others by arranging for sponsors provide promotional sponsorships by affiliating their goods and services with sports exhibitions, art shows, live music concerts | ACTIVE | — |
| 042 | Technical provision and support for data processing systems, namely, providing technology information in the field of data processing and technical support services in the nature of troubleshooting computer software problems in connection with data processing; Providing temporary use of online, non-downloadable software for accessing patient treatment databases and donor databases; Providing technological and scientific information about scientific laboratory services and blood banks, in particular medical research laboratories; Providing of scientific information derived from analysis of medical diagnostic results; Blood analysis services for scientific research purposes; Scientific laboratory services; Chemical laboratories and medical research laboratories; Scientific research in the field of physics; Chemistry services, namely, chemical analysis, chemical laboratories; Chemical analysis; Scientific testing services, namely, blood testing for scientific research purpose; Blood testing for scientific research purposes, with said testing entailing the filtration, separation and centrifugation of blood; Laboratory trials, namely, medical and scientific research in the nature of conducting clinical trials for others; Development and further development of data processing computer software and hardware in the field of laboratory medicine and blood and plasma collection; Database development services, namely, creation of medical databases in digital form; Scientific and medical research in the medical and pharmaceutical fields; Scientific and medical research in the field of chemistry and biology; Development and establishment of testing specifications and procedures for the medical industry, namely, development of medical equipment procedures and test procedures, donation procedures, and medical instrument procedures; Data processing services, namely, technical and scientific registration and processing of patient treatment data and donor data in databases; Scientific laboratory services | ACTIVE | — |
| 044 | Medical analysis services for diagnostic and treatment purposes provided by medical laboratories in connection with blood and plasma donation and clinical medical consultations in connection with the same; Pharmacy advice, namely, providing medical advice in the field of pharmaceuticals; providing of medical information in relation to blood donation centres; Providing of medical and pharmaceutical support via telephone, namely, providing medical information; Medical services featuring blood fractionation or blood transfusion for medical purposes; Medical services in the nature of blood sampling or collection; Blood examination in the nature of medical blood analysis services for diagnostic treatment purposes; medical assistance; blood bank services; Blood bank services in the nature of blood donation centres; Blood bank services in the nature of blood extraction stations; Services in the field of immunotherapy, namely, medical care; Nursing home services; Medical care, namely, immunotherapy; Providing medical information, namely, medical diagnostic information through medical results; Medical care, namely, conducting medical diagnostics within the framework of conducting medical examinations; Blood bank services, namely, conducting of blood donation, including platelet donations, SDR donation being erythrocyte, whole blood donation, plasma donation, and autologous donation being multiple type of cellular donations from an individual; Medical care, namely, execution of medical and clinical examination services; nutrition consultation; Providing medical opinions in the nature of medical advice in the field of weight loss, dermatology, hematology; health counseling; Medical services, namely, transfusion or transplantation of blood and blood components; Medical services; Rental of medical equipment; Rental of medical equipment in the nature of medical diagnostic instruments and apparatus for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Haema GmbH
- Other trademarks owned by Haema GmbH
- Other trademarks owned by Haema GmbH
- Other trademarks owned by Haema AG
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TRANSFUSIUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 9, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 2, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 23, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 23, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 14, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 14, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 26, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 26, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 26, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 8, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 8, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 2, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 3, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 22, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 4, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 4, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 31, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 28, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 28, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 24, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |